Cardio Diagnostics Holdings, Inc.

NasdaqCM CDIO

Cardio Diagnostics Holdings, Inc. Shareholders' Equity for the quarter ending September 30, 2024

Cardio Diagnostics Holdings, Inc. Shareholders' Equity is NA for the quarter ending September 30, 2024. Shareholders' equity are the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Cardio Diagnostics Holdings, Inc. Shareholders' Equity for the quarter ending September 30, 2023 was USD 2.29 M.

Key data

Date	Shareholders' Equity	Minority Interest	Total Equity	Total Stockholders Equity and Liabilities

NasdaqCM: CDIO

Cardio Diagnostics Holdings, Inc.

CEO	Dr. Meeshanthini V. Dogan Ph.D.
IPO Date	Jan. 14, 2022
Location	United States
Headquarters	400 N Aberdeen St
Employees	7
Sector	Health Care
Industries Clinical Trials Biotechnology

Description

Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease risk assessment test. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is based in Chicago, Illinois.

Key trends

Past 5 years